DIPAL DOSHI

Corporate Board Profile

Tech Score: 0/100

Azenta, Inc.

Filing Date	Source Excerpt
2024-12-17	Dipal Doshi \| Age 49 \| (Director Nominee) Committees: Audit, ESG Other Current Public Boards: Entrada Therapeutics (NASDAQ: TRDA) Former Public Boards: None Education: BA, Rutgers University; MBA, University of Pennsylvania Career Highlights: Mr. Doshi is the CEO of Entrada Therapeutics and a Member of its Board of Directors. He previously served as President and CEO from 2017 to 2023. Mr. Doshi has led critical functions in biotechnology and pharmaceutical companies, including roles focused on business development, corporate strategy, new product planning, commercial planning and finance. Prior to joining Entrada, Mr. Doshi was the Chief Business Officer at Amicus Therapeutics, a global biotechnology company focused on rare diseases. He has also held senior-level positions at a healthcare private equity fund and Catalent. Earlier in his career, Mr. Doshi worked in Merrill Lynch’s Investment Banking Group and held several roles at Eli Lilly and Company. Key Expertise Provided to the Board: Mr. Doshi brings significant experience in the biotechnology and pharmaceutical industries. His experience in strategy, operational and commercial growth, and perspective as a current public company CEO will be additive to the Board. Key Skills: Executive Leadership in Life Sciences/Healthcare, Public Company Executive Experience, Growth Strategies and Market Expansion, Operations Experience Compensation: No compensation disclosed.

Filing Date

Source Excerpt

2024-12-17

Dipal Doshi | Age 49 | (Director Nominee) Committees: Audit, ESG Other Current Public Boards: Entrada Therapeutics (NASDAQ: TRDA) Former Public Boards: None Education: BA, Rutgers University; MBA, University of Pennsylvania Career Highlights: Mr. Doshi is the CEO of Entrada Therapeutics and a Member of its Board of Directors. He previously served as President and CEO from 2017 to 2023. Mr. Doshi has led critical functions in biotechnology and pharmaceutical companies, including roles focused on business development, corporate strategy, new product planning, commercial planning and finance. Prior to joining Entrada, Mr. Doshi was the Chief Business Officer at Amicus Therapeutics, a global biotechnology company focused on rare diseases. He has also held senior-level positions at a healthcare private equity fund and Catalent. Earlier in his career, Mr. Doshi worked in Merrill Lynch’s Investment Banking Group and held several roles at Eli Lilly and Company. Key Expertise Provided to the Board: Mr. Doshi brings significant experience in the biotechnology and pharmaceutical industries. His experience in strategy, operational and commercial growth, and perspective as a current public company CEO will be additive to the Board. Key Skills: Executive Leadership in Life Sciences/Healthcare, Public Company Executive Experience, Growth Strategies and Market Expansion, Operations Experience Compensation: No compensation disclosed.

Data sourced from SEC filings. Last updated: 2026-02-03